For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | ||
|---|---|---|---|---|
| Research and development | 165,577 | 443,541.5* | ||
| General and administrative | 978,576 | 910,194.25* | ||
| Total operating expenses | 1,144,153 | 1,353,735.75 | ||
| Loss from operations | -1,144,153 | -1,353,735.75* | ||
| Interest expense | 1,943 | 18,164.75* | ||
| Loss on change in fair value of derivative liabilities | - | -1,578* | ||
| Loss (gain) on extinguishment of debt | - | 81,586.25* | ||
| Total other expense (income), net | -1,943 | 61,843.5* | ||
| Loss before provision for income taxes | -1,146,096 | -1,291,892.25 | ||
| Net loss | -1,146,096 | -1,291,892.25 | ||
| Basic EPS | -0.13 | -0.165 | ||
| Diluted EPS | 0.13 | -0.165 | ||
| Basic Average Shares | 8,701,837 | 7,812,264 | ||
| Diluted Average Shares | 8,701,837 | 7,812,264 | ||
ADAPTIN BIO, INC. (APTN)
ADAPTIN BIO, INC. (APTN)